Crossject

  • Biotech or pharma, therapeutic R&D
  • Medical device or technology

Crossject is a specialty pharmaceutical company developing medicines for emergency situations utilizing its award-winning needle-free auto-injector ZENEO® platform and portfolio of drug /device combinations.


CROSSJECT is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) (contract number 75A50122C0003).

The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency drugs via intramuscular injection on bare skin or even through clothing.


Crossject's needle free auto-injection platform can be adapted to different liquid drug formulations in order to improve patients or caregiver usability, safety and injection reliability.


Crossject is currently ISO in-licensing opportunities synergistic to the ZENEO® auto injector in its IM and SC configurations.

Address

Dijon
Burgundy
France

Website

https://www.crossject.com

Contact Exhibitor


Loading
View all Partnering Companies

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS